Trial Profile
Transitioning toiIntravenous Remodulin (treprostinil sodium) from inhaled iloprost (Ventavis) in patients with pulmonary arterial hypertension: safety, efficacy and treatment satisfaction
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Sponsors United Therapeutics Corporation
- 09 Nov 2007 Status changed from recruiting to discontinued
- 17 Apr 2007 New trial record.